(NASDAQ:OTLY), MALMÖ, Sweden, Jan. 12, 2026 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY), the world's original and largest oat drink company, will report financial results for the fourth quarter ended December 31, 2025, on Wednesday February 11, 2026 before the U.S. market opens. Oatly will host a conference call and webcast at 8:00 a.m. […]

(NYSE:GXO), GREENWICH, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO) will hold its fourth quarter and full-year 2025 earnings conference call and webcast on Wednesday, February 11, 2026, at 8:30 a.m. Eastern Time. The company's results will be released after market close on Tuesday, February 10, 2026, and made available at

(NASDAQ:VFF), Product portfolio expansion aligns with legacy market consumer preferences and global shift toward convenience 10 new product offerings include the first regulated blunt in market as well as infused spliffs and other pre-roll formats DRACHTEN, The Netherlands, Jan. 12, 2026 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF),

(NASDAQ:GLPI), WYOMISSING, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) announced today that the Company will release its 2025 fourth quarter financial results after the market close on Thursday, February 19, 2026. The Company will host a conference call at 10:00 a.m. ET on Friday, February 20, 2026. During

(NASDAQ:LYRA), WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company's lead product candidate for the treatment of chronic rhinosinusitis (CRS). The Company also announced a workforce reduction impacting its remaining

(ASX – Trade24:RAD),(AUST:RAD.AX),(NASDAQ:RADX), Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm Theranostics Leading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase I therapeutic trial in multiple solid tumors expected to dose the first patient in Q1 2026 First clinical

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 12, 2026 Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in 2026, as well as regulatory

New Crypto Mutuum Finance (MUTM) Raises Over $19.7M and Moves Through Roadmap Phase 2 GlobeNewswire January 12, 2026 DUBAI, United Arab Emirates, Jan. 12, 2026 (GLOBE NEWSWIRE) — In every cycle, there are periods when quiet development begins turning into visible progress. That moment often happens when a new protocol enters its operational roadmap and

Sharps Technology and Coinbase Expand Relationship with Launch of Institutional-Grade Solana Validator GlobeNewswire January 12, 2026 NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (“STSS” or the “Company”) (NASDAQ: STSS), a medical device company implementing a Solana-based digital asset treasury strategy, today announced the expansion of its relationship with Coinbase Institutional, a

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI(R) in the At-Home Setting GlobeNewswire January 12, 2026 Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI(R) in At-Home Setting as Early as Year-End 2026 BioXcel